Surgalign to Participate at the 2023 AAOS Annual Meeting OrthoDome in Las Vegas
03 Mars 2023 - 2:30PM
Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital surgery, today announced its
participation at the 2023 American Academy of Orthopaedic Surgeons
(“AAOS”) Annual Meeting, which will take place March 7-11, 2023 in
Las Vegas, Nevada.
Over this five-day event, industry will gather to discuss the
latest evidence-based advancements that are transforming the way
medical professionals care for their patients. The Company is a
participating sponsor of OrthoDome, an AAOS Annual Meeting
experience that offers an immersive and comfortable video theater
room showcasing orthopaedic surgical techniques and devices in 4K
resolution video, narrated by live experts and chaired by Ronald A.
Navarro, MD, FAAOS and Lisa K. Cannada, MD, FAAOS. On Wednesday,
March 8, 2023, Dr. Vacarro will moderate the Spine Panel –
OrthoDome session HT01 – taking place from 8:00 a.m. –
9:30 a.m. PT. This panel will include live discussions and video
demonstrations from leading spine surgeons including:
- Barrett I. Woods, MD, FAAOS
- David Kate, MD
- Jose A. Canseco, MD, PhD
- Victor W. Hsu, MD, FAAOS
- Rick C. Sasso, MD, FAAOS
Rick Sasso, MD, is a founding member and the president of
Indiana Spine Group, the first practice to utilize the Company’s
HOLO Portal Surgical Guidance System following receipt of U.S. Food
& Drug Administration (“FDA”) 510(k). Dr. Sasso is a
board-certified orthopaedic surgeon, specializing in spine surgery.
He is also a professor and chief of spine surgery at the Indiana
University School of Medicine, Department of Orthopaedic Surgery.
Dr. Sasso will present “AI through the Continuum of Care”, which
features Surgalign’s HOLO AI and HOLO Portal technologies as
applied to diagnostic imaging, intra-operative surgical guidance,
and population analytics.
Terry Rich, President and CEO of Surgalign, commented, “AAOS
continues to help industry advance technologies and improve patient
care, and we are especially excited for this year’s event, given
the focus on spine care and the best technologies that drive better
patient outcomes. We can’t thank Dr. Sasso and his team enough for
their support as we work to commercialize HOLO Portal and leverage
our HOLO AI platform to expand the use of AI and AR in the medical
field.”
With FDA clearance, HOLO Portal became the world’s first
surgical guidance system to incorporate artificial intelligence
(“AI”) and augmented reality (“AR”). The first procedure was
performed at Indiana Spine Hospital in Carmel, Indiana and since,
over 30 cases have been performed. The HOLO Portal system’s AI
processes intraoperative images to autonomously segment and label
the anatomy and plan patient-specific pedicle screw trajectories
that are approved by the surgeon. The system uses AR to overlay the
segmented AI reconstruction over the patient’s actual anatomy,
providing real-time 3D visualization throughout the surgical
procedure, helping surgeons visualize trajectories, while guiding
surgical instruments.
To learn more about Surgalign’s Digital Health and HOLO AI
Technology, please visit us online at:
https://surgalign.com/digital-health/.
About Surgalign Holdings, Inc.Surgalign
Holdings, Inc. is a global medical technology company committed to
the promise of digital health to drive transformation across the
surgical landscape. Uniquely aligned and resourced to advance the
standard of care, the company is building technologies physicians
and other health providers will look to for what is truly possible
for their patients. Surgalign is focused on developing solutions
that predictably deliver superior clinical and economic outcomes.
Surgalign markets products throughout the United States and in
approximately 50 countries worldwide through an expanding network
of top independent distributors. Surgalign is headquartered in
Deerfield, IL, with commercial, innovation and design centers in
San Diego, CA, Warsaw and Poznan, Poland, and Wurmlingen, Germany.
Learn more at www.surgalign.com and connect on LinkedIn, Twitter
and Instagram.
Forward Looking StatementsThis press release
contains forward-looking statements including, without limitation,
statements relating the intended use of proceeds from the
registered direct offering. These forward-looking statements are
based on management’s current expectations, estimates and
projections about our industry, our management’s beliefs and
certain assumptions made by our management. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” variations of such words and similar expressions are
intended to identify such forward-looking statements. Factors that
could cause actual results to differ materially from those
forward-looking statements include: (i) the Company’s access to
adequate operating cash flow, trade credit, borrowed funds and
equity capital to fund its operations and pay its obligations as
they become due, and the terms on which external financing may be
available, including the impact of adverse trends or disruption in
the global credit and equity markets; (ii) risks relating to
existing or potential litigation or regulatory actions; (iii) the
identification of control deficiencies, including material
weaknesses in internal control over financial reporting; (iv)
general worldwide economic conditions and related uncertainties;
(v) the continued impact of the COVID-19 and the Company’s attempts
at mitigation, particularly in international markets served by the
Company; (vi) the failure by the Company to identify, develop and
successfully implement its strategic initiatives, particularly with
respect to its digital surgery strategy; (vii) the reliability of
our supply chain; (viii) our ability to meet obligations, including
purchase minimums, under our vendor and other agreements; (ix)
whether or when the demand for procedures involving our products
will increase; (x) our financial position and results, total
revenue, product revenue, gross margin, and operations; (xi)
failure to realize, or unexpected costs in seeking to realize, the
expected benefits of the Holo Surgical Inc. (“Holo Surgical”) and
Inteneural Networks Inc. (“INN”) acquisitions, including the
failure of Holo Surgical’s and INN’s products and services to be
satisfactorily developed or achieve applicable regulatory approvals
or as a result of the failure to commercialize and distribute its
products; (xii) the failure to effectively integrate Holo
Surgical’s and INN’s operations with those of the Company,
including: retention of key personnel; the effect on relationships
with customers, suppliers, and other third parties; and the
diversion of management time and attention to the integration;
(xiii) the number of shares and amount of cash that will be
required in connection with any post-closing milestone payments,
including as a result of changes in the trading price of the
Company’s common stock and their effect on the amount of cash
needed by the Company to fund any post-closing milestone payments
in connection with the acquisitions; (xiv) the continuation of
recent quality issues with respect to our global supply chain; and
(xv) the effect and timing of changes in laws or in governmental
regulations. These factors should be considered carefully, and
undue reliance should not be placed on the forward-looking
statements. Each forward-looking statement in this communication
speaks only as of the date of the particular statement.
These forward-looking statements are not guarantees of future
performance and are subject to various risks and uncertainties,
including market and other conditions and the risks identified in
Surgalign’s most recent Annual Report on Form 10-K and other
filings with the SEC. Our actual results may differ materially from
the anticipated results reflected in these forward-looking
statements. Copies of Surgalign’s SEC filings may be obtained
without charge by visiting Surgalign’s website
at www.surgalign.com or the SEC’s website
at www.sec.gov. We undertake no obligation to update
these forward-looking statements except as may be required by
law.
Investor Relations and Media Relations
Contact:Glenn WienerE-Mail: gwiener@surgalign.comTel: +1
917 887 8434
Surgalign (NASDAQ:SRGA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Surgalign (NASDAQ:SRGA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024